首页> 外文期刊>European Journal of Pharmacology: An International Journal >Novel selective hypotensive vasopressin peptides: cardiovascular and structure-activity-relationship studies.
【24h】

Novel selective hypotensive vasopressin peptides: cardiovascular and structure-activity-relationship studies.

机译:新型选择性降压血管加压素肽:心血管和结构-活性-关系研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Recently, we discovered a series of peripheral acting selective hypotensive vasopressin peptides. Whether these peptides may interact with receptors outside the vasopressin receptor family and affect cardiac function could not be excluded. Accordingly, we tested the effects of these hypotensive vasopressin peptides on blood pressure and heart rate in intact rats and on the heart rate, ventricular contractile force and coronary flow of isolated perfused rat hearts. We found that the hypotensive vasopressin peptides did not modify cardiac function, either in vivo or in vitro. The vasodepressor potency was reduced when assayed in rats with vasopressin-maintained baseline blood pressure, suggesting that vasopressin and the hypotensive peptide compete for a common vasodilating vasopressin receptor in the vasculature. We have now synthesized more potent and radioiodinatable hypotensive peptides that could serve as lead compounds for the development of a radiomarker for the putative vasodilating vasopressin receptor.
机译:最近,我们发现了一系列外围作用的选择性降压血管加压素肽。这些肽是否可能与血管加压素受体家族之外的受体相互作用并影响心脏功能尚不能排除。因此,我们测试了这些降压加压素肽对完整大鼠的血压和心率以及离体灌注大鼠心脏的心率,心室收缩力和冠状动脉血流的影响。我们发现降压血管加压素肽在体内或体外均未改变心脏功能。在使用加压素维持的基线血压的大鼠中进行测定时,其降压药效能降低,表明加压素和降压肽竞争脉管系统中常见的血管舒张加压素受体。现在,我们已经合成了更有效和放射性碘化的降压肽,这些肽可以用作先导化合物,用于开发假定的血管舒张加压素受体的放射性标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号